NICE rejects bosutinib for chronic myeloid leukaemia
Patients with previously treated chronic myeloid leukaemia (CML) will not be prescribed bosutinib on the NHS after the National Institute for Health and Care Excellence recommended against its use.
Even with a patient access scheme, bosutinib did not offer enough benefit to justify its price, said Andrew Dillon, NICE’s chief executive. “Although there is evidence to suggest bosutinib can be considered to be clinically effective for the treatment of CML, limitations in the evidence provided by the manufacturer meant that actual benefit compared to other treatments in terms of the estimated effect on overall survival was unclear,” he said.
Bosutinib is licensed for the treatment of adult patients with chronic phase, accelerated phase, and blast phase Philadelphia chromosome-positive chronic myelogenous leukaemia previously treated with one or more tyrosine kinase inhibitors and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options, according to the summary of product characteristics.
Patients who are already taking bosutinib will be able to continue with the medication until they and their clinician decides it is appropriate to stop, NICE added.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2013.11131069